Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants

about

Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants

Item

http://www.wikidata.org/entity/Q58697074

description

im Oktober 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Collateral resistance to taxan ...... ogen receptor and its variants

@en

Collateral resistance to taxan ...... ogen receptor and its variants

@nl

type

Item

label

Collateral resistance to taxan ...... ogen receptor and its variants

@en

Collateral resistance to taxan ...... ogen receptor and its variants

@nl

prefLabel

Collateral resistance to taxan ...... ogen receptor and its variants

@en

Collateral resistance to taxan ...... ogen receptor and its variants

@nl

P1476

Collateral resistance to taxan ...... ogen receptor and its variants

@en

P2093

Ario Takeuchi

http://www.w3.org/2001/XMLSchema#string

Eiji Kashiwagi

http://www.w3.org/2001/XMLSchema#string

Junichi Inokuchi

http://www.w3.org/2001/XMLSchema#string

Katsunori Tatsugami

http://www.w3.org/2001/XMLSchema#string

Kenjiro Imada

http://www.w3.org/2001/XMLSchema#string

Masatoshi Eto

http://www.w3.org/2001/XMLSchema#string

Shunichi Kajioka

http://www.w3.org/2001/XMLSchema#string

Takashi Dejima

http://www.w3.org/2001/XMLSchema#string

Takeshi Uchiumi

http://www.w3.org/2001/XMLSchema#string

Yoshiaki Yamamoto

http://www.w3.org/2001/XMLSchema#string

P2860

Abiraterone in metastatic prostate cancer without previous chemotherapy

Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Alpha emitter radium-223 and survival in metastatic prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

P304

3224-3234

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CAS.13751

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Masaki Shiota

P577

2018-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30051622

http://www.w3.org/2001/XMLSchema#string

P921

cancer research

P932

6172053

http://www.w3.org/2001/XMLSchema#string